CA1208217A - 2-(0-carboxyphenylamino)-6h-pyrimido(2,1-b)- quinazolone-6 et ses derives; methode de preparation et applications - Google Patents

2-(0-carboxyphenylamino)-6h-pyrimido(2,1-b)- quinazolone-6 et ses derives; methode de preparation et applications

Info

Publication number: CA1208217A
Authority: CA; Canada
Prior art keywords: pyrimido; quinazolone; carboxyphenylamino; acid; formula
Prior art date: 1982-08-20
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA000409872A

Other languages

English (en)

Inventor

Vera A. Portnyagina

Valentina K. Karp

Irina S. Barkova

Fedor P. Trinus

Alexandra G. Fadeicheva

Nikolai A. Mokhort

Galina I. Kozhushko

Nikolai F. Danilevsky

Viktor M. Sidelnikov

Yakov P. Solsky

Tatyana K. Ryabukha

Jury D. Usenko

Alexandr G. Panteleimonov

Galina A. Getman

Adolf A. Medvedovsky

Jury N. Dobrovolsky

Viktor V. Kljushin

Larisa M. Kirichek

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

KIEVSKY NAUCHNO-ISSLEDOVATELSKY INSTITUT FARMAKOLOGII I TOXIKOLOGII

Original Assignee

KIEVSKY NAUCHNO-ISSLEDOVATELSKY INSTITUT FARMAKOLOGII I TOXIKOLOGII

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1982-08-20

Filing date

1982-08-20

Publication date

1986-07-22

1982-08-20 Application filed by KIEVSKY NAUCHNO-ISSLEDOVATELSKY INSTITUT FARMAKOLOGII I TOXIKOLOGII filed Critical KIEVSKY NAUCHNO-ISSLEDOVATELSKY INSTITUT FARMAKOLOGII I TOXIKOLOGII

1982-08-20 Priority to CA000409872A priority Critical patent/CA1208217A/fr

1986-07-22 Application granted granted Critical

1986-07-22 Publication of CA1208217A publication Critical patent/CA1208217A/fr

Status Expired legal-status Critical Current

Links

238000000034 method Methods 0.000 title claims description 32
RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 claims abstract description 54
BTTNYQZNBZNDOR-UHFFFAOYSA-N 2,4-dichloropyrimidine Chemical compound ClC1=CC=NC(Cl)=N1 BTTNYQZNBZNDOR-UHFFFAOYSA-N 0.000 claims abstract description 17
150000001875 compounds Chemical class 0.000 claims abstract description 14
159000000000 sodium salts Chemical class 0.000 claims abstract description 9
150000003839 salts Chemical class 0.000 claims abstract description 7
125000003710 aryl alkyl group Chemical group 0.000 claims abstract description 6
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 6
150000001408 amides Chemical class 0.000 claims abstract description 5
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims abstract 8
101150009274 nhr-1 gene Proteins 0.000 claims abstract 5
239000012431 aqueous reaction media Substances 0.000 claims abstract 2
239000012430 organic reaction media Substances 0.000 claims abstract 2
238000002360 preparation method Methods 0.000 claims description 25
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 18
239000000126 substance Substances 0.000 claims description 16
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 15
230000008569 process Effects 0.000 claims description 14
239000000203 mixture Substances 0.000 claims description 13
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 11
238000006243 chemical reaction Methods 0.000 claims description 5
239000003960 organic solvent Substances 0.000 claims description 5
239000012736 aqueous medium Substances 0.000 claims description 3
239000002609 medium Substances 0.000 claims 1
239000000376 reactant Substances 0.000 claims 1
230000000973 chemotherapeutic effect Effects 0.000 abstract description 8
239000002260 anti-inflammatory agent Substances 0.000 abstract description 6
239000012429 reaction media Substances 0.000 abstract 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 27
239000000243 solution Substances 0.000 description 21
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
239000002253 acid Substances 0.000 description 16
239000007795 chemical reaction product Substances 0.000 description 16
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 15
238000000354 decomposition reaction Methods 0.000 description 15
206010030113 Oedema Diseases 0.000 description 14
238000002844 melting Methods 0.000 description 14
230000008018 melting Effects 0.000 description 14
230000001741 anti-phlogistic effect Effects 0.000 description 12
239000002244 precipitate Substances 0.000 description 12
241000700159 Rattus Species 0.000 description 11
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
230000000694 effects Effects 0.000 description 10
UQZKYYIKWZOKKD-UHFFFAOYSA-N orphenadrine hydrochloride Chemical compound [Cl-].C=1C=CC=C(C)C=1C(OCC[NH+](C)C)C1=CC=CC=C1 UQZKYYIKWZOKKD-UHFFFAOYSA-N 0.000 description 10
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
239000000463 material Substances 0.000 description 9
238000011282 treatment Methods 0.000 description 9
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 8
229960004279 formaldehyde Drugs 0.000 description 8
-1 o-carboxyphenylamino Chemical group 0.000 description 8
229910052708 sodium Inorganic materials 0.000 description 8
239000011734 sodium Substances 0.000 description 8
241001465754 Metazoa Species 0.000 description 7
206010061218 Inflammation Diseases 0.000 description 6
108010058846 Ovalbumin Proteins 0.000 description 6
230000000202 analgesic effect Effects 0.000 description 6
230000004054 inflammatory process Effects 0.000 description 6
230000005764 inhibitory process Effects 0.000 description 6
230000004048 modification Effects 0.000 description 6
238000012986 modification Methods 0.000 description 6
238000012360 testing method Methods 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
238000002347 injection Methods 0.000 description 5
239000007924 injection Substances 0.000 description 5
229940092253 ovalbumin Drugs 0.000 description 5
238000003756 stirring Methods 0.000 description 5
VEXDRERIMPLZLU-UHFFFAOYSA-N 3-hydroxy-2-methylbutanoic acid Chemical compound CC(O)C(C)C(O)=O VEXDRERIMPLZLU-UHFFFAOYSA-N 0.000 description 4
230000007059 acute toxicity Effects 0.000 description 4
231100000403 acute toxicity Toxicity 0.000 description 4
150000001298 alcohols Chemical class 0.000 description 4
230000001754 anti-pyretic effect Effects 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 3
229920000742 Cotton Polymers 0.000 description 3
206010018691 Granuloma Diseases 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
206010030124 Oedema peripheral Diseases 0.000 description 3
ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 3
238000010171 animal model Methods 0.000 description 3
230000002322 anti-exudative effect Effects 0.000 description 3
230000003110 anti-inflammatory effect Effects 0.000 description 3
239000002585 base Substances 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
235000010418 carrageenan Nutrition 0.000 description 3
229920001525 carrageenan Polymers 0.000 description 3
238000001816 cooling Methods 0.000 description 3
238000011161 development Methods 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
150000002148 esters Chemical class 0.000 description 3
230000002757 inflammatory effect Effects 0.000 description 3
230000003993 interaction Effects 0.000 description 3
229960002895 phenylbutazone Drugs 0.000 description 3
VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 3
239000000047 product Substances 0.000 description 3
238000001953 recrystallisation Methods 0.000 description 3
229960004025 sodium salicylate Drugs 0.000 description 3
230000000638 stimulation Effects 0.000 description 3
XJPZKYIHCLDXST-UHFFFAOYSA-N 4,6-dichloropyrimidine Chemical compound ClC1=CC(Cl)=NC=N1 XJPZKYIHCLDXST-UHFFFAOYSA-N 0.000 description 2
KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 2
208000017667 Chronic Disease Diseases 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
241000282326 Felis catus Species 0.000 description 2
206010020565 Hyperaemia Diseases 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
244000299461 Theobroma cacao Species 0.000 description 2
235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 2
235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 2
230000001028 anti-proliverative effect Effects 0.000 description 2
239000002221 antipyretic Substances 0.000 description 2
206010003246 arthritis Diseases 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
210000003445 biliary tract Anatomy 0.000 description 2
235000001046 cacaotero Nutrition 0.000 description 2
125000001309 chloro group Chemical group Cl* 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 2
150000002170 ethers Chemical class 0.000 description 2
125000004494 ethyl ester group Chemical group 0.000 description 2
239000000945 filler Substances 0.000 description 2
230000002496 gastric effect Effects 0.000 description 2
230000006872 improvement Effects 0.000 description 2
229960000905 indomethacin Drugs 0.000 description 2
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
238000011835 investigation Methods 0.000 description 2
239000007788 liquid Substances 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
230000000877 morphologic effect Effects 0.000 description 2
230000001338 necrotic effect Effects 0.000 description 2
239000003883 ointment base Substances 0.000 description 2
230000000079 pharmacotherapeutic effect Effects 0.000 description 2
DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 2
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000000829 suppository Substances 0.000 description 2
238000011287 therapeutic dose Methods 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
BLDFSDCBQJUWFG-UHFFFAOYSA-N 2-(methylamino)-1,2-diphenylethanol Chemical compound C=1C=CC=CC=1C(NC)C(O)C1=CC=CC=C1 BLDFSDCBQJUWFG-UHFFFAOYSA-N 0.000 description 1
PXBFMLJZNCDSMP-UHFFFAOYSA-N 2-Aminobenzamide Chemical compound NC(=O)C1=CC=CC=C1N PXBFMLJZNCDSMP-UHFFFAOYSA-N 0.000 description 1
JLWMMYZWEHHTFF-UHFFFAOYSA-N 2-[6-(3-carbamimidoylphenoxy)-4-[di(propan-2-yl)amino]-3,5-difluoropyridin-2-yl]oxy-5-(2-methylpropylcarbamoyl)benzoic acid Chemical compound OC(=O)C1=CC(C(=O)NCC(C)C)=CC=C1OC1=NC(OC=2C=C(C=CC=2)C(N)=N)=C(F)C(N(C(C)C)C(C)C)=C1F JLWMMYZWEHHTFF-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
IYLLULUTZPKQBW-UHFFFAOYSA-N Acrinol Chemical compound CC(O)C(O)=O.C1=C(N)C=CC2=C(N)C3=CC(OCC)=CC=C3N=C21 IYLLULUTZPKQBW-UHFFFAOYSA-N 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
241000700198 Cavia Species 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
240000001624 Espostoa lanata Species 0.000 description 1
235000009161 Espostoa lanata Nutrition 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
208000003433 Gingival Pocket Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
108010003272 Hyaluronate lyase Proteins 0.000 description 1
102000001974 Hyaluronidases Human genes 0.000 description 1
239000004166 Lanolin Substances 0.000 description 1
102100026933 Myelin-associated neurite-outgrowth inhibitor Human genes 0.000 description 1
206010028851 Necrosis Diseases 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
244000018633 Prunus armeniaca Species 0.000 description 1
235000009827 Prunus armeniaca Nutrition 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
208000033464 Reiter syndrome Diseases 0.000 description 1
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
SMEGJBVQLJJKKX-HOTMZDKISA-N [(2R,3S,4S,5R,6R)-5-acetyloxy-3,4,6-trihydroxyoxan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O)OC(=O)C)O)O SMEGJBVQLJJKKX-HOTMZDKISA-N 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
229940081735 acetylcellulose Drugs 0.000 description 1
230000009471 action Effects 0.000 description 1
210000004100 adrenal gland Anatomy 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000003513 alkali Substances 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
230000002421 anti-septic effect Effects 0.000 description 1
229940064004 antiseptic throat preparations Drugs 0.000 description 1
ZXVOCOLRQJZVBW-UHFFFAOYSA-N azane;ethanol Chemical compound N.CCO ZXVOCOLRQJZVBW-UHFFFAOYSA-N 0.000 description 1
JPYQFYIEOUVJDU-UHFFFAOYSA-N beclamide Chemical compound ClCCC(=O)NCC1=CC=CC=C1 JPYQFYIEOUVJDU-UHFFFAOYSA-N 0.000 description 1
239000000440 bentonite Substances 0.000 description 1
229910000278 bentonite Inorganic materials 0.000 description 1
SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
238000004820 blood count Methods 0.000 description 1
210000001772 blood platelet Anatomy 0.000 description 1
235000014121 butter Nutrition 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
150000001805 chlorine compounds Chemical class 0.000 description 1
230000007665 chronic toxicity Effects 0.000 description 1
231100000160 chronic toxicity Toxicity 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000000994 depressogenic effect Effects 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
239000003814 drug Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000003925 fat Substances 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
239000010685 fatty oil Substances 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
235000019256 formaldehyde Nutrition 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
201000005562 gingival recession Diseases 0.000 description 1
239000008103 glucose Substances 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
210000002216 heart Anatomy 0.000 description 1
230000001744 histochemical effect Effects 0.000 description 1
230000002962 histologic effect Effects 0.000 description 1
229960002773 hyaluronidase Drugs 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
229910001867 inorganic solvent Inorganic materials 0.000 description 1
239000003049 inorganic solvent Substances 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
229940039717 lanolin Drugs 0.000 description 1
235000019388 lanolin Nutrition 0.000 description 1
230000003902 lesion Effects 0.000 description 1
231100000636 lethal dose Toxicity 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
IAIWVQXQOWNYOU-FPYGCLRLSA-N nitrofural Chemical compound NC(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 IAIWVQXQOWNYOU-FPYGCLRLSA-N 0.000 description 1
229960001907 nitrofurazone Drugs 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000002674 ointment Substances 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000008533 pain sensitivity Effects 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
230000036285 pathological change Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
239000008023 pharmaceutical filler Substances 0.000 description 1
230000000793 phophlogistic effect Effects 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
229940068984 polyvinyl alcohol Drugs 0.000 description 1
235000019422 polyvinyl alcohol Nutrition 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
229960000957 prothipendyl Drugs 0.000 description 1
230000036647 reaction Effects 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
208000002574 reactive arthritis Diseases 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
229960001860 salicylate Drugs 0.000 description 1
YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
229940076279 serotonin Drugs 0.000 description 1
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
241000894007 species Species 0.000 description 1
239000012177 spermaceti Substances 0.000 description 1
229940084106 spermaceti Drugs 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
239000000725 suspension Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
229960001322 trypsin Drugs 0.000 description 1
210000001835 viscera Anatomy 0.000 description 1
239000001993 wax Substances 0.000 description 1

Landscapes

Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA000409872A 1982-08-20 1982-08-20 2-(0-carboxyphenylamino)-6h-pyrimido(2,1-b)- quinazolone-6 et ses derives; methode de preparation et applications Expired CA1208217A (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA000409872A CA1208217A (fr)	1982-08-20	1982-08-20	2-(0-carboxyphenylamino)-6h-pyrimido(2,1-b)- quinazolone-6 et ses derives; methode de preparation et applications

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA000409872A CA1208217A (fr)	1982-08-20	1982-08-20	2-(0-carboxyphenylamino)-6h-pyrimido(2,1-b)- quinazolone-6 et ses derives; methode de preparation et applications

Publications (1)

Publication Number	Publication Date
CA1208217A true CA1208217A (fr)	1986-07-22

Family

ID=4123454

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000409872A Expired CA1208217A (fr)	1982-08-20	1982-08-20	2-(0-carboxyphenylamino)-6h-pyrimido(2,1-b)- quinazolone-6 et ses derives; methode de preparation et applications

Country Status (1)

Country	Link
CA (1)	CA1208217A (fr)

1982
- 1982-08-20 CA CA000409872A patent/CA1208217A/fr not_active Expired

Legal Events

Date	Code	Title	Description
2003-07-22	MKEX	Expiry

Publication	Publication Date	Title
US4225610A (en)	1980-09-30	Immunoactivators derived from amino thiazoles
US3505349A (en)	1970-04-07	2-nitro-imidazolyl-1-acetamides
DE3027075C2 (fr)	1989-05-18
US4226861A (en)	1980-10-07	N-Lower-alkyl 3-phenoxy-1-azetidinecarboxamides
US4281127A (en)	1981-07-28	Trans-3-(4-oxo-4H-quinazolin-3-yl)-2-propenoic acid derivatives
US4313949A (en)	1982-02-02	Method of producing an inhibitory effect on blood platelet aggregation
US4503073A (en)	1985-03-05	2-Amino-3-(alkylthiobenzoyl)-phenylacetic acids
US4249021A (en)	1981-02-03	Indanacetic acid compounds
TW211563B (fr)	1993-08-21
JPS60174792A (ja)	1985-09-09	メチレンジホスホン酸誘導体、その製造方法および抗リウマチ用薬剤組成物
EP0005559B1 (fr)	1981-11-04	Dérivés d'acide phénylaminothiophène-acétique, procédé pour leur préparation et médicaments les contenant
JPH0153266B2 (fr)	1989-11-13
KR840000763B1 (ko)	1984-06-08	2-아미노-3-벤조일-페닐아세트아미드의 제조방법
US3812109A (en)	1974-05-21	Substituted indenyl glucoronide esters
CA1208217A (fr)	1986-07-22	2-(0-carboxyphenylamino)-6h-pyrimido(2,1-b)- quinazolone-6 et ses derives; methode de preparation et applications
EP0134928A1 (fr)	1985-03-27	Dérivés de l'imidazo[1,5-a]pyrimidine et procédé pour leur préparation
US4173646A (en)	1979-11-06	Tricyclicdicarboximides
US4061763A (en)	1977-12-06	Tricyclicdicarboximides
US3896223A (en)	1975-07-22	Anti-inflammatory thiazole compositions and methods for using same
JPS5867618A (ja)	1983-04-22	１―アザキサントンからなる医薬
US4006233A (en)	1977-02-01	N-(pyrimidinyl)-tricyclo[3(or 4).2.2.02,4(or 5) ]-non (or dec)ene-dicarboximides
EP0105131A1 (fr)	1984-04-11	2-(Omega-alkylaminoalkyle)- et 2-(omega-dialkylaminoalkyle)-3-(4-X-benzylidène)-phtalimides
US4042702A (en)	1977-08-16	Halogen pyrazole derivatives, a method for producing these halogen pyrazole derivatives, medicaments containing and methods of using them
CS217997B2 (en)	1983-02-25	Method of making the new derivatives of the pyrimidine
US3974176A (en)	1976-08-10	Halogen pyrazoles derivatives, a method for producing these halogen pyrazole derivatives and medicaments containing them